Navigation Links
Experimental drug shows promise in advanced kidney cancer
Date:9/26/2007

Barcelona, Spain: A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.

The study, presented today (Wednesday) at the European Cancer Conference (ECCO 14) in Barcelona, showed that the experimental drug, axitinib, shrank tumours and delayed progression of the disease in a group of patients who are among the toughest to treat.

In the study, scientists gave axitinib to 62 patients whose kidney cancer had spread and who had not benefited from a standard treatment, sorafenib, a targeted therapy designed to disrupt cell division signals in cancer cells and block the tumours ability to form new blood vessels that help it grow. Fourteen of the patients also had been given to no avail another similarly targeted drug, sunitinib, after the sorafenib had failed to work. Axitinib works similarly to the other two but is believed to be more potent.

More than half the patients 51 percent experienced tumour shrinkage and in 23 percent of them the shrinkage is considered significant, said lead investigator Dr Brian I. Rini, an associate professor of medicine at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, USA, and a paid member of the Pfizer scientific advisory board. Preliminary analysis shows the progression-free survival was on average more than 7.7 months. We think these results are impressive because these patients were heavily pre-treated and with drugs thought to be similar to axitinib.

The disease progressed in only 24 percent of patients, which we think is low in this kind of setting, Rini added. The study found the tumour remained stable in 37 percent of the patients.

Historically, metastatic kidney cancer has been very tough to treat, with a median survival of 12 months. Through the results of this trial, it appears that axitinib is a very active drug in renal cell cancer that can benefit a large
'/>"/>

Contact: Emma Ross
rosswrite@mac.com
34-932-308-832
ECCO-the European CanCer Conference
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Experimental treatment for Ebola Virus Shows promising results in mice
2. FDA approves Phase 0 trial which tests experimental drugs on humans
3. Experimental drug to fight flu
4. Experimental SARS Vaccine
5. Experimental vaccine for shingles is effective
6. Experimental Blood Test May Spot Heart Attack Risk, Study Says
7. Five AIDS Patients To Receive Experimental Anti-retroviral Drugs
8. TMC 114 and 125 experimental drugs to be tested on four HIV patients
9. Protection against HIV and Herpes is possible with the Experimental Microbicide
10. Experimental Therapy Effective Against Malignant Melanoma in Horses
11. Experimental Alzheimer’s Drug curbs the disease in mic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale Capital ... announced the closing of a $118 million FHA-insured loan modification refinancing for Johnston ... Smithfield and Clayton, North Carolina. JHSC is a joint venture of Johnston ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... Scale-up Online Seminar featuring researchers from Lubrizol, Pfizer, and Merck. This ... EDT. , Process development project timelines often require informed decisions with limited process ...
(Date:8/4/2015)... Washington, DC (PRWEB) , ... August 04, 2015 , ... ... Services, Inc.’s (AIS) in-house research team, can now be accessed at http://www.AISHealth.com . ... in AIS’s Directory of Health Plans: 2015, the tables and charts on the website’s ...
(Date:8/4/2015)... ... August 04, 2015 , ... Half of consumers ... is board-certified is increasingly influential in their choice of practitioner, according to new ... Consumer Survey on Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical ...
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental Trading Company, Inc., the ... and school supplies, has developed engaging and affordable teacher supplies based on the ... student rewards, classroom decorations, crafts and educational resources featuring Carle’s vibrant illustrations and ...
Breaking Medicine News(10 mins):Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3
... appearance of a cold sore is,a sign that your ... emerge, according to John Sherman, ND, noted naturopathic,physician and ... 80% and 90% of the adult population have the ... Dr. Sherman, who,is the author of The Complete Botanical ...
... Patient safety incidents cost the federal Medicare ... preventable deaths during 2004 through 2006, according to ... Study. HealthGrades, analysis of 41 million Medicare patient ... had, on average, a 43 percent lower chance ...
... WALTHAM, Mass., April 7, 2008 Repligen,Corporation (Nasdaq: ... and,Chief Executive Officer, Walter C. Herlihy, Ph.D., will host ... at 9:00 a.m. EDT, to provide,an update on the ... Thomson/CCBN and can be accessed via,Repligen,s website at ...
... from China is no cause for alarm , , MONDAY, ... probable case of human-to-human transmission of bird flu in ... that there,s a genetic component to human-to-human transmission of ... "This suggests that there,s some genetic component to resistance ...
... ALB ) will hold its quarterly conference call to ... ET., This call is being webcast by Thomson/CCBN and ... in the Investor,Information section., To listen ... In # 800-591-6942 International Dial In ...
... April 7, 2008 American Media, Inc. (AMI),today ... corporate website certain,information currently required to be disclosed ... its amended Senior Secured Credit Agreement., The ... certain key magazine titles during the period April ...
Cached Medicine News:Health News:A Cold Sore Is Often A Warning Sign of Deeper Health Issues, Expert Says 2Health News:Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study 2Health News:Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study 3Health News:Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study 4Health News:Repligen Announces Conference Call to Update Orencia(R) Lawsuit 2Health News:Repligen Announces Conference Call to Update Orencia(R) Lawsuit 3Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 2Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 3Health News:Albemarle Corporation's First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 8:00am ET 2
(Date:8/4/2015)... Aug. 4, 2015  Ironshore Pharmaceuticals & Development, ... Health, a company specializing in personalized medicine, to ... trial, designed to evaluate the safety and efficacy ... treat Attention-deficit/hyperactivity disorder (ADHD). This is Restore,s second ... Health originally partnered with Ironshore in 2014 and ...
(Date:8/3/2015)... 4, 2015   The Intellectual Property and ... leading provider of intelligent information for businesses and ... CMR Pharmaceutical R&D Factbook , the biopharmaceutical industry,s ... around declines in R&D, the analysis identifies a ... milestone and forecasts sales to reach $1.3 trillion ...
(Date:8/3/2015)... , Aug. 3, 2015  BC Technical, the nation,s ... Ohio Valley Medical Systems, one of the largest MRI ... addition of Ohio Valley Medical Systems allows BC Technical ... Hitachi MRI.   "We couldn,t be more ... President and CEO of BC Technical. "The Ohio Valley ...
Breaking Medicine Technology:Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2Pharma Sales to Grow Beyond $1 Trillion 2BC Technical Acquires Ohio Valley Medical Systems 2
... Radioactive Microspheres in... -- ROME, August 19, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... Reportlinker.com announces that a new market research ... Advances in Large Scale BioManufacturing and Scale-Up ... A Comprehensive Study of ... This new ASM study provides a clear view ...
Cached Medicine Technology:Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 2Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 3Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 4Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 5Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 6Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 7Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 8Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 9Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED 2Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED 3
... This therapeutic system is ... patient in mind. As ... and ongoing therapy, SONOCUR ... and effective therapy. Plus, ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... only one of the most modern lithotripters available ... from being designed for the treatment of the ... the MODULITH SLX can also be employed for ... equally suitable for the treatment of gallstones or ...
... The MINILITH SL1 developed by STORZ MEDICAL ... extensive experience in the field of kidney ... the specific requirements to be met by ... as has been outlined above. The MINILITH ...
Medicine Products: